Sacral Neuromodulation for Male Overactive Bladder (MOAB)
To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.
Overactive Bladder|Urinary Urgency Incontinence|Benign Prostatic Hyperplasia|Prostate Cancer|Prostatectomy
DEVICE: Axonics SNM System
Adverse event reporting (Safety), Device related, procedure-related and all serious adverse events, 6 months, 1 year|Performance/Effectiveness - Improvement in Qualify of Life scoring, International Consultation of Incontinence Questionnaire Overactive Bladder Qualify of Life (ICIQ-OABqol): questions in each subscale are scored by a summed range of 0 to 100, with a higher score indicating better quality of life. Overall score ≥ 10 points from baseline to follow-up is indicative of a clinically meaningful improvement., 6 months, 1 year|Performance/Effectiveness - Reduction in UUI episodes, Demonstrate a ≥ 50% reduction in the number of UUI episodes on a 3-day diary, 6 months, 1 year
To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients who have a prior history of radical prostatectomy or radiation for prostate cancer or who have a history of cytoreductive surgical intervention for benign prostatic hyperplasia (BPH).